Kidney Transplant Clinical Trials: Recruiting Studies
Recruiting kidney transplant clinical trials, listed from live ClinicalTrials.gov records with each trial's official title, phase, conditions, locations and a direct link to its full record.
These listings cover recruiting studies in kidney transplantation — including medicines to prevent rejection, graft monitoring and care after transplant — exactly as the ClinicalTrials.gov records describe them. A listing here is not a recommendation: transplant trials have strict eligibility criteria, and any change to transplant care must go through your own transplant team.
Trial data from ClinicalTrials.gov, fetched November 17, 2026 — always confirm details on the trial's own page.
Recruiting trials, most recently updated first
Showing the 20 most recently updated recruiting trials from a search that matched 254 records in total on the fetch date. The full, live list is on ClinicalTrials.gov.
Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to prevent rejection. Currently the main limitation of kidney transplantation is the occurrence of chronic graft dysfunction due to the CNI nephrotoxicity. Thus, strategies to minimize or stop CNI have been developed as belatacept, a…
1 study locations, none listed in the United States (including Nantes, Loire Atlantique).
Prospective Imaging-based Assessment of Skeletal Deterioration After Kidney Transplantation Using DXA and HR-pQCT (DXACT Study)
The goal of this observational study is to learn how bone health changes during the first year after kidney transplantation in adults receiving their first kidney transplant. The main questions it aims to answer are: * How many patients show a clinically relevant decline in bone density or bone structure within 12…
1 study locations, none listed in the United States (including Innsbruck, Tyrol).
Evaluation of the Outcomes of Kidney Biopsies in Deceased Donors in the Emilia-Romagna Region
The KT-BX-RER Study is a multicenter observational cohort study, with both retrospective and prospective components, designed to evaluate pre-implant kidney biopsies from deceased donors in the Emilia-Romagna Region and to compare findings between donors after circulatory death (DCD) and donors after brain death…
3 study locations, none listed in the United States (including Bologna, Italy; Modena, Italy; Parma, Italy).
Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are: How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit…
27 study locations, 19 in the United States (including Los Angeles, California; Sacramento, California).
Evaluation gériatrique Avant Transplantation rénale
Geriatric assessment is now widely used to decide whether older patients with chronic kidney disease should be put on the kidney transplantation waiting list. This study aims to evaluate the association between Geriatric assessment and inscription on kidney transplantation.
1 study locations, none listed in the United States (including Caen, France).
Phase 1 Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
The goal of this clinical trial is to learn if a GalKO Porcine Thymokidney can maintain renal function, without the need for dialysis, after transplantation into adult subjects with End Stage Renal Disease.
2 study locations, 2 in the United States (including New York, New York).
A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? *…
7 study locations, none listed in the United States (including Helsinki, Finland; Paris, France; Rome, Italy).
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Currently, the monitoring of children receiving a kidney transplantation includes surveillance biopsies to detect subclinical rejection and signs of toxicity of immunosuppressive drugs (tacrolimus). The hypothesis of the study is that the combination of non-invasive biomarkers (Donor-derived cell-free DNA and…
1 study locations, none listed in the United States (including Paris, France).
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Operationally Seamless Phase 2/3 Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of AIC263029 in the Treatment of BKV Infection in Kidney Transplant Recipients
The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia). The study will also examine how the body processes AIC263029 and whether it lowers BKV levels in the blood. Researchers will compare AIC263029 to a…
14 study locations, 14 in the United States (including Birmingham, Alabama; Los Angeles, California).
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
33 study locations, none listed in the United States (including Recife, Pernambuco; Botucatu, São Paulo; São Paulo, São Paulo).
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.
7 study locations, 7 in the United States (including San Diego, California; San Francisco, California; Atlanta, Georgia).
A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Mezagitamab (TAK-079) in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
Antibody-mediated rejection (AMR) is a major cause of worsening kidney function after a kidney transplant (kidney allograft dysfunction) and can lead to kidney failure. AMR happens when the kidney recipient's immune system makes antibodies that attack the donor kidney. Antibodies are proteins made by the immune system…
35 study locations, 14 in the United States (including Los Angeles, California; San Francisco, California; Miami, Florida).
Il Registro Italiano di Dialisi Pediatrica (RIDP) - Italian Registry of Pediatric Dialysis
The primary aim of the Registry, in addition to promoting collaboration and the sharing of protocols among participating centres, is to collect epidemiological, clinical, and biochemical data on patients, as well as technical data on dialysis treatments performed at Italian dialysis centres.
12 study locations, none listed in the United States (including Ancona, Italy; Bari, Italy; Bologna, Italy).
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular disease (for example, heart attack, stroke, heart failure) is the commonest complication of kidney failure. Kidney transplantation reduces cardiovascular risk but cardiovascular disease remains the commonest cause of death in patients following transplantation. Current strategies to assess patient's…
5 study locations, none listed in the United States (including Edinburgh, Lothian; Glasgow, United Kingdom; London, United Kingdom).
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI is a type of injury to small blood vessels in the transplanted kidney and may be a sign of rejection by the body. It…
53 study locations, 25 in the United States (including Loma Linda, California; Los Angeles, California).
Integrated Multidisciplinary Non-Pharmacological Treatment for Improving Health-Related Quality of Life in Solid Organ Transplant Recipients: A Randomized Single-Center Pilot Study
This is a single-center interventional study aimed at evaluating the feasibility of a multidisciplinary non-pharmacological approach based on acupuncture, telerehabilitation-based physical rehabilitation, and brain health programs to improve health-related quality of life (HRQoL) and psychophysical well-being in…
1 study locations, none listed in the United States (including Palermo, Palermo).
Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1)…
8 study locations, 8 in the United States (including San Francisco, California; Miami, Florida; Atlanta, Georgia).
A Phase 1, Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Letermovir in Pediatric Kidney Transplant (KT) Recipients Less Than 18 Years of Age and Weighing Less Than 40 Kilograms
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if…
22 study locations, 22 in the United States (including Birmingham, Alabama; Los Angeles, California).
Conversion From Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of Functional, Safety and Quality of Life Outcomes (CIRTEN SPK)
This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 20 Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no more than 5 years prior, with a history of tremors following transplantation.
1 study locations, 1 in the United States (including Madison, Wisconsin).
Fecal Microbiota Transplantation (FMT CAPSULE DE, FMPCapDE, MTP-CP101) in Kidney Stone Patients (FMT IND STUDY)
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones. Adults with high urine calcium or high urine oxalate will receive antibiotic pretreatment followed by microbial capsules. Changes in 24-hour urine calcium…
1 study locations, 1 in the United States (including Park City, Utah).
More from the Clinical Trials Finder
This page is general information only. It is not medical advice, it does not say whether any trial is right for you, and it makes no promise about eligibility or enrollment. Clinical trials have eligibility criteria set by the trial team, and taking part is always voluntary. Talk to your own care team before contacting any trial, and confirm every detail on the trial's own ClinicalTrials.gov page.